|European Patent Office||Published Application||WO 2018/081436||05/03/2018||2017-037|
|Japan||Published Application||WO 2018/081436||05/03/2018||2017-037|
|Patent Cooperation Treaty||Published Application||WO2018081436||05/03/2018||2017-037|
Additional Patents Pending
Lymphatic Valve formation is associated with lymphangiogenesis, a pathological event that occurs in many diseases after inflammatory, infections, immunogenic or traumatic insults. These valves play critical roles in directing lymph flow inside the lymphatic vessels. The Lymphatic pathway is a primary mediator of immune responses, including transplant rejection. The current regimen of pharmacotherapy with corticosteroids is of limited efficacy and is fraught with serious side effects.
Researchers at the University of California, Berkeley have identified Itga-9 is critically involved in lymphatic valve formation after pathological insults, and itga-9 blockade can reduce the number of lymphatic valves formed inside the pathological lymphatic vessels. Moreover, Itga-9 interference can be used to modulate immune responses and transplant rejection. Additionally, ITga-9 can be used to improve the therapeutic effects of other anti-lymphangiogenic molecules, such as VEGFR-3. When used in combination, the formulation of both valves and lymphatic vessels are greatly suppressed and better therapeutic outcomes can be achieved for severe diseases, such as high-risk transplant rejection.